Characterization of the Immuno-inflammatory Response Involved in Bone Destruction During Periodontitis: Study on Biological Samples With Collection

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

Periodontitis is a major public health problem because it is widespread in the adult population. It leads to the irreversible destruction of the anchoring tissues of the teeth, and represents a modifiable risk factor for systemic inflammatory pathologies. This chronic inflammatory disease, which is associated with oral dysbiosis involving Porphyromonas gingivalis, is triggered by a permissive immune response. It is preceded by a reversible clinical phase, during which there is no bone resorption process: gingivitis. The understanding of the key mechanisms involved in the evolution from gingivitis to periodontitis, which will allow to early identify patient at risk of periodontitis, remain unclear at this time. Neutrophils are the main cells of inflammation present within the periodontal pockets. The excess of certain neutrophils or the alteration of their functions is associated with the triggering of periodontitis, whereas their activity, finely orchestrated, would be a key to periodontal homeostasis. It is likely that some periodontal bacteria, including P. gingivalis, but also products of matrix catabolism could deregulate the physiological functions of neutrophils towards pro-inflammatory and catabolic profiles. Moreover, to date, the differentiation and role of neutrophil subsets in periodontal homeostasis as well as in gingivitis and its evolution into periodontitis remain poorly studied. The investigators hypothesize that various subsets of neutrophils may play different roles during the development of periodontitis (evolution of gingivitis to periodontitis). The primary objective is to characterize neutrophil subtypes associated with periodontal destruction during periodontitis. Secondary objectives are : 1. Identify specific interactions of tissue-activated neutrophils with the matrix microenvironment during periodontitis 2. Identify specific interactions of tissue or oral (salivary) activated neutrophils with the oral microbiota during periodontitis 3. Identify specific oral (salivary) neutrophil subtypes in periodontal health, gingivitis and periodontitis 4. Evaluate the function, including pro-osteoclastogenic function, of oral neutrophils compared to blood neutrophils stimulated by infection

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

⁃ Common criteria for all patient groups

• Patient \> 18 years old

• Patient affiliated to a national health insurance

• Patient who speaks and understands French well enough to be able to read and understand the study information note.

• Patient who does not object to his participation in the study

⁃ Specific Criteria :

• Control Group = BOP \< 10%, PI\<20%, PD≤ 3mm

• Gingivitis cases = BOP ≥ 10%, PD≤ 3mm

• Periodontitis cases = BOP ≥ 10%, PD\> 3mm

Locations
Other Locations
France
Charles-Foix Hospital
RECRUITING
Ivry-sur-seine
Contact Information
Primary
Marjolaine Gosset, PU-PH
marjolaine.gosset@u-paris.fr
01 49 59 48 11
Backup
François Ferré, MCU-PH
françois.ferre@aphp.fr
01 49 59 48 11
Time Frame
Start Date: 2025-04-30
Estimated Completion Date: 2028-05-15
Participants
Target number of participants: 60
Treatments
Periodontitis Cases
Patients with stage 3 or 4 periodontitis (Chicago 2017) ; BOP ≥ 10%, PD≥ 4mm Patients requiring surgical care such as dental avulsion or pre-prosthetic periodontal surgeries
Gingivitis Cases
BOP ≥ 10%, PD≤ 3mm according to Chicago 2017 Patients requiring surgical care such as dental avulsion or pre-prosthetic periodontal surgeries
Control
BOP \< 10%, PD≤ 3mm Patients with gingival health on intact or reduced periodontium without a history of periodontitis and requiring surgical care such as dental avulsion or aesthetic surgeries
Related Therapeutic Areas
Sponsors
Leads: Assistance Publique - Hôpitaux de Paris

This content was sourced from clinicaltrials.gov